Press Release - Company Data

Immunomedics Reports IMMU-130 is Active in Patients With Irinotecan-Refractory Colorectal Cancer
Posted 2014-06-01 23:35NAI Editing
today reported 10 of 14 patients (71%) with metastatic colorectal cancer (mCRC) responded to IMMU-130, the Company's novel investigational antibody-drug conjugate (ADC) that comprises an anti-CEACAM5

Immunomedics Prices $30 Million Public Offering of Common Stock
Posted 2014-05-02 00:17NAI Editing
today announced the pricing of an underwritten public offering of 9 million shares of its common stock, offered at a price to the public of $3.35 per share.

Immunomedics Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as a Potential Novel Platform for Treating Cancer
Posted 2014-04-07 23:37NAI Editing
a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported resul

Immunomedics Appoints Richard L. Sherman to Board of Directors
Posted 2013-08-20 03:07NAI Editing
a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that

Immunomedics Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases
Posted 2013-07-15 23:33NAI Editing
a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the i

Immunomedics Reports First Results From Phase Ib Study of 90Y-Clivatuzumab in Patients With Metastatic Pancreatic Cancer After 2 or More Prior Therapies
Posted 2013-07-02 23:30NAI Editing
a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced enco

Immunomedics Presents Epratuzumab's Mechanism of Action in Systemic Lupus Erythematosus
Posted 2013-06-12 23:33NAI Editing
a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that

Immunomedics Reports That UCB Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLE
Posted 2013-06-12 23:32NAI Editing
a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that

Immunomedics Reports Progress With Labeling Proteins, Including Antibodies, for Improved PET Imaging
Posted 2013-06-12 00:32NAI Editing
a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported progr

Combination of 90Y-Epratuzumab and Veltuzumab is Active in Non-Hodgkin Lymphoma
Posted 2013-06-10 23:31NAI Editing
a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that